Skip to content

Study · Randomized controlled trial · n = 9,340 · 2019

4 results

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial.

Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA

JAMA cardiology1 Dec 2019Cited by 51 (Europe PMC)

PMID31721979 (opens in a new tab)PMCIDPMC6865601 (opens in a new tab)DOI10.1001/jamacardio.2019.3080 (opens in a new tab)PepBankPUB-31721979
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk, liraglutide was associated with a 15.7% lower relative risk of total MACE than placebo (HR 0.84).

    In plain wordsIn adults with type 2 diabetes at high heart risk, liraglutide was linked to 15.7% fewer first and repeat major heart events than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal (first and recurrent) MACE
    Study

    n = 9,340

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    up to 1.8 mg per day · 3.5 to 5.0 yearsAs given in this study (human).

    Measurements

    Hazard ratio
    0.84 HR
    total MACE

    Source sentences

    Summary
    Liraglutide was associated with a 15.7% relative risk reduction in total MACE (hazard ratio [HR], 0.84; 95% CI, 0.76-0.93)
    2 context sentences
    Summary · context
    This post hoc analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) randomized, double-blind, clinical trial included data from patients with type 2 diabetes who had established or were at high risk for cardiovascular disease at 410 sites in…
    Summary · context
    Patients were randomized 1:1 to receive liraglutide (up to 1.8 mg per day) or placebo, both with standard care, for 3.5 to 5.0 years.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk, liraglutide was associated with a 13.4% reduction in total expanded MACE compared with placebo (HR 0.87).

    In plain wordsIn adults with type 2 diabetes at high heart risk, liraglutide was linked to 13.4% fewer expanded major heart events than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal expanded MACE
    Study

    n = 9,340

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    up to 1.8 mg per day · 3.5 to 5.0 yearsAs given in this study (human).

    Measurements

    Hazard ratio
    0.87 HR
    total expanded MACE

    Source sentences

    Summary
    a 13.4% reduction in total expanded MACE (HR, 0.87; 95% CI, 0.81-0.93) compared with placebo.
    2 context sentences
    Summary · context
    This post hoc analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) randomized, double-blind, clinical trial included data from patients with type 2 diabetes who had established or were at high risk for cardiovascular disease at 410 sites in…
    Summary · context
    Patients were randomized 1:1 to receive liraglutide (up to 1.8 mg per day) or placebo, both with standard care, for 3.5 to 5.0 years.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk, fewer first and recurrent MACE occurred with liraglutide than with placebo.

    In plain wordsIn adults with type 2 diabetes at high heart risk, fewer first and repeat major heart events occurred with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseNumber of first and recurrent MACE events
    Study

    n = 9,340

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    up to 1.8 mg per day · 3.5 to 5.0 yearsAs given in this study (human).

    Source sentences

    Summary
    Fewer first and recurrent MACE occurred in the liraglutide group (n = 4668; 608 first and 127 recurrent events) than in the placebo group (n = 4672; 694 first and 176 recurrent events).
    2 context sentences
    Summary · context
    This post hoc analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) randomized, double-blind, clinical trial included data from patients with type 2 diabetes who had established or were at high risk for cardiovascular disease at 410 sites in…
    Summary · context
    Patients were randomized 1:1 to receive liraglutide (up to 1.8 mg per day) or placebo, both with standard care, for 3.5 to 5.0 years.
  4. 04HumanRandomized controlled trialEfficacy outcome

    For most individual cardiovascular end points, liraglutide was associated with lower risk than placebo.

    In plain wordsFor most single heart outcomes, liraglutide was linked to lower risk than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseIndividual cardiovascular end points
    Study

    n = 9,340

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    up to 1.8 mg per day · 3.5 to 5.0 yearsAs given in this study (human).

    Source sentences

    Summary
    For most individual cardiovascular end points, liraglutide was associated with lower risk vs placebo.
    2 context sentences
    Summary · context
    This post hoc analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) randomized, double-blind, clinical trial included data from patients with type 2 diabetes who had established or were at high risk for cardiovascular disease at 410 sites in…
    Summary · context
    Patients were randomized 1:1 to receive liraglutide (up to 1.8 mg per day) or placebo, both with standard care, for 3.5 to 5.0 years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.